Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, looking exclusively at women.
May 20 2024Medtronic Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement , the SMall Annuli Randomized To Evolut or SAPIEN Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve was associated with significantly less bioprosthetic valve dysfunction and improved quality of life for women with symptomatic severe aortic stenosis .
Results demonstrated the primary clinical endpoint for composite of death, disabling stroke, or heart failure rehospitalization was similar amongst women with AS and small annulus randomized to balloon-expandable valve or SEV at one year. However, , compared to a balloon-expandable valve, the Evolut SEV was associated with significantly less BVD , less prosthesis-patient mismatch , less mild or greater total aortic regurgitation , and improved quality of life in women with AS and small annulus.
Aortic Stenosis Healthcare Medicine Stenosis Technology Transcatheter Aortic Valve Replacement
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
SMART trial reaffirms hemodynamic superiority of TAVR self-expanding valveAdditional analysis from the SMall Annuli Randomized To Evolut or SAPIEN (SMART) study demonstrated clinical non-inferiority of self-expanding valves (SEV) versus balloon-expandable valves (BEV) in aortic stenosis patients undergoing transcatheter aortic valve replacement (TAVR) and confirmed valve performance superiority over time based on...
Weiterlesen »
New data reveals optimal timing for percutaneous coronary intervention in TAVR patientsNew data reveals that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery disease (CAD).
Weiterlesen »
TAVR associated with lower in-hospital complications in patients with aortic stenosis and cardiogenic shockA nationwide observational analysis of patients with aortic stenosis (AS) and cardiogenic shock (CS) who underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) determined that patients who underwent TAVR had lower in-hospital complications and resource utilization compared with SAVR.
Weiterlesen »
Transcatheter valve replacement outcomes similar to surgery for severe aortic stenosisA new study demonstrates parity between a minimally invasive procedure to replace the aortic valve in the heart—transcatheter aortic valve replacement (TAVR)—and surgical aortic valve replacement (SAVR).
Weiterlesen »
Large registry data demonstrate PCI for stable CAD can be safely performed before, during or after TAVRNew data reveal that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery disease (CAD).
Weiterlesen »
Crystal Palace Women promoted to Women's Super League after clinching Women's Championship titleCrystal Palace Women have won the Women's Championship for the first time to earn promotion to the WSL for the 2024/25 season.
Weiterlesen »